Taldefgrobep alfa did not significantly improve motor function across the total population of treated spinal muscular atrophy (SMA) patients in a pivotal Phase 3 clinical trial, but significant improvements were seen among Caucasian participants. That’s according to trial results announced by the therapy’s developer, Biohaven Pharmaceuticals. The…
